Summary. Data are presented on 81 multiple myeloma (MM) patients with renal failure (creatinine . 176´8 mmol/ l) at the time of autologous stem cell transplantation (auto-SCT), including 38 patients on dialysis. The median age was 53 years (range: 29±69) and 26% had received more than 12 months of prior chemotherapy. CD34

SLED is a viable alternative to traditional continuous renal replacement therapies for critically ill patients in whom IHD has failed or been withheld, although prospective studies directly comparing two modalities are required to define the exact role for SLED in this setting.

No abstract